Evidence map›Paper›PMID 39436116›Full record

Observational studyPediatric pulmonology2025

Efficacy and tolerance of intravenous methylprednisolone pulses in children with severe bronchopulmonary dysplasia requiring respiratory support.

Josseline Reynaud, Lélia Dreyfus, Laurianne Coutier, Marine Butin, Isabelle Godbert, Florent Baudin, Côme Horvat, Philippe Reix

Abstract readObservational Study
In one paragraph

Observational study in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Josseline ReynaudService de pneumologie pédiatrique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France.
Lélia DreyfusService de néonatologie et Réanimation Néonatale, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France.ORCID http://orcid.org/0000-0002-1863-3098
Laurianne CoutierService de pneumologie pédiatrique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France.ORCID http://orcid.org/0000-0002-0888-1995
Marine ButinService de néonatologie et Réanimation Néonatale, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France.ORCID http://orcid.org/0000-0001-9453-4641
Isabelle GodbertService de néonatologie et Réanimation Néonatale, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.
Florent BaudinRéanimation pédiatrique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France.ORCID http://orcid.org/0000-0002-0838-8914
Côme HorvatUrgences pédiatriques, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France.
Philippe ReixService de pneumologie pédiatrique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France.ORCID http://orcid.org/0000-0002-9192-8335

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesBronchopulmonary dysplasia (BPD) is a chronic lung disease that affects premature babies and contributes to their morbidity. French BPD guidelines suggest the use of intravenous methylprednisolone pulses (IVMP) for those who require respiratory support (RS) following 36 weeks postmenstrual age (PMA). However, there is scant data on the efficacy and tolerance for this indication. Our objectives were to assess the efficacy and tolerance of IVMP in patients with severe BPD requiring RS. STUDY AND

designThis retrospective observational study included preterm infants (<32 weeks gestational age) treated by IVMP between January 2016 and March 2021, in a single tertiary care hospital. The primary endpoint was signified by changes in the Pulmonary Severity Score (PSS). Our secondary endpoints were changes in RS and the tolerance of IVMP.

resultsData of 14 children with BPD under RS were reviewed. Their median [IQR] gestational age at birth was (26[26-29.5] weeks). After IVMP administration, the PSS did not improve significantly from baseline day 0 (D0) (0.85[0.55-1.15]) to D7 (0.74 [0.48-1.00]) or Month 1 (1.02 [0.57-1.48]). Three children (21%) experienced a decrease in RS in the following month of IVMP. There was no negative short-term impact on growth. Five infants presented infectious complications. The development quotient was measured in 5 children at 2 years of age.

conclusionIn our study, IVMP did not improve PSS and it was associated with a high number of infections. Other studies are needed to better define the place of IVMP in these infants.

Indexed as

Bronchopulmonary DysplasiaGlucocorticoidsMethylprednisoloneAdministration, IntravenousFemaleGestational AgeHumansInfantInfant, NewbornInfant, PrematureMaleRespiration, ArtificialRetrospective StudiesSeverity of Illness IndexTreatment OutcomeGlucocorticoidsMethylprednisolonebronchopulmonary dysplasiacorticosteroidsinfantmethylprednisolone pulsesrespiratory supportsevere

Identifiers

PMID39436116
PMCPMC11731323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.